TGTX Jumps As TG Therapeutics Hikes 2026 Revenue Outlook

TG Therapeutics Inc. stocks have been trading up by 9.62 percent amid strong sentiment from promising multiple sclerosis treatment news.

Spot the Next Big Runner

Click Here for a Millionaire's POV on Trading TGTX

SUBSCRIBE FOR ALERTS

JOIN 50,000+ ACTIVE TRADERS

What Traders Need To Know

Q2 2026 revenue came in around $240M, with U.S. BRIUMVI sales up 64% year over year to $227.7M, beating revenue expectations near $230M.
Management lifted 2026 revenue guidance to roughly $950M, driven by a stronger U.S. BRIUMVI outlook of $890–$905M and a targeted $1B U.S. BRIUMVI run rate exiting 2026.
EPS of $0.05 missed estimates in the $0.31–$0.44 range, but revenue still grew about 70% year over year, underscoring rapid scaling despite margin pressure.
B. Riley raised its TGTX price target to $86 from $55, while the Street’s average target sits near $64, signaling broad bullish sentiment on TG Therapeutics Inc.
Takeover rumors from Betaville drove a recent 4% bounce to $52.82 after a sharp 10.6% drop to $46.52, highlighting event-driven volatility around TGTX.

Weekly Update Aug 17 – Aug 21, 2026: On Saturday, August 22, 2026 TG Therapeutics Inc. stock [NASDAQ: TGTX] is trending up by 9.62%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.

Healthcare industry expert:

Analyst sentiment – positive

TG Therapeutics sits in a strong commercializing-biotech niche with a single but rapidly scaling MS asset, BRIUMVI. Revenue of ~$616M and 3‑year CAGR >220% place it at the upper end of commercial-stage peers, with exceptional 92.7% gross margin and improving operating leverage (double‑digit EBIT margin despite heavy R&D/SG&A). Cash of ~$483M and a 4.3 current ratio offset elevated leverage (D/E 1.25, interest coverage 2.5). Valuation is rich (P/S ~9.7, P/E ~18), but justified by growth and >80% ROIC.

Price action shows a decisive, high‑volume breakout: shares moved from ~$49 to $55.42 this week, taking out prior resistance around $52 and closing near the highs, consistent with aggressive institutional buying. Five‑minute candles confirm persistent bid support on intraday dips into the low‑50s. Dominant trend is up. For trading, $52 is the key actionable level: above it, maintain a long bias; a sustained break below $52 would likely trigger faster mean reversion toward the high‑40s.

More Breaking News

Fundamentals and news flow create a powerful setup relative to biotech benchmarks. Guidance raise to ~$950M FY26 revenue and a ~$1B BRIUMVI U.S. run‑rate, positive Phase 3 ENHANCE data, and a de‑risked subcutaneous program materially outpace typical mid‑cap biotech trajectories. Takeover speculation and Street targets in the mid‑60s to mid‑80s add support. Versus Healthcare and Biotech indices, TGTX offers superior growth and profitability; a 12‑month base‑case target of $70 with support at $52 and resistance near $65 is warranted.

Quick Financial Overview

TG Therapeutics Inc. is trading on a strong growth story anchored by BRIUMVI. Q2 2026 revenue of about $240M reflects roughly 70% year-over-year growth, with U.S. BRIUMVI sales at $227.7M. That kind of concentration tells traders where the real engine is. Management backing this with a 2026 revenue guide of around $950M and plans to exit 2026 at a $1B U.S. BRIUMVI run rate reinforces a clear, product-led ramp.

On the margin side, TGTX posts a very high gross margin near 92.7%, which gives room to fund heavy R&D and sales spend. Profitability is already in place, with a profit margin above 55% on a trailing basis, but Q2 EPS of $0.05 missed Street expectations. For short-term traders, that gap explains some of the post-earnings volatility, even as the balance sheet remains solid with strong cash and free cash flow support from operations.

Technically, the weekly tape shows an aggressive recovery move. Shares bounced from around $49.28 to a close near $55.42 over a few days, with intraday action spiking from $51.10 to as high as $56.87 before settling at $54.27. That wide intraday range signals active momentum trading around TGTX, fueled by the guidance hike, analyst target increases, and takeover chatter. For active traders, volatility itself is the opportunity, but it also raises position-size risk.

Conclusion

TG Therapeutics Inc. now sits at the intersection of strong fundamentals and elevated event risk. Revenue is ramping fast, guidance has been raised to about $950M for 2026, and BRIUMVI is clearly driving the story. The company supports this with robust gross margins and a clean cash profile, while ongoing Phase 3 work and new indications aim to extend the franchise. That combination is what keeps analysts positive and has driven price target lifts on TGTX.

For traders, the other side of that coin is volatility. An EPS miss, a 10.6% single-session drop, and then a sharp rebound on takeover rumors show how quickly sentiment can swing. The weekly and intraday charts both highlight wide ranges and strong momentum bursts, which reward disciplined entries and tight risk control. TGTX offers a classic growth-stock setup: powerful top-line trajectory, rich expectations, and a news-heavy calendar.

The key for active traders is to respect both the upside potential from BRIUMVI and the downside shocks that can follow any disappointment or rumor reversal. That’s why routine and process matter so much when approaching a volatile name like this. As Tim Bohen, lead trainer with StocksToTrade says, “A consistent trading routine beats sporadic action every time. Show up daily, and you’ll start to see the patterns others miss.” As I tell my students when they study names like TG Therapeutics Inc., “The best trades come when you align strong fundamentals with clean technical levels, but you still size every position as if the next candle can prove you wrong.” This article is for educational and research purposes only.

This is stock news, not investment advice. StocksToTrade News delivers real-time stock market updates tailored to highlight the key catalysts driving short-term price movements. Our coverage is designed for active traders and investors who thrive in fast-moving markets, with a focus on volatile sectors like penny stocks, AI stocks, Robinhood stocks and other momentum plays. From earnings reports and FDA approvals to mergers, new contracts, and unusual trading volume, we break down the events that can spark significant price action.

Looking to level up your trading game? Explore StocksToTrade, the ultimate platform for traders. With powerful tools designed for swing and day trading, integrated news scanning, and even social media monitoring, StocksToTrade keeps you one step ahead.

Check out our quick startup guide for new traders!

Ready to build your watchlists? Check out these curated lists:

Once your watchlist is set, take the next step and trade with confidence using StocksToTrade’s robust platform. Don’t miss out — grab your 14-day trial for just $7 and experience the edge you need to thrive in today’s fast-paced markets.

Start Your Trial Now!